Fred Aslan, Artiva CEO, on Cell Therapy’s Next Wave, RA Trials & Scalable NK Platforms

What It Covers

Fred Aslan, CEO of Artiva Biotherapeutics, explains how allogeneic NK cell therapy addresses the core limitations of autologous CAR-T — cost, scalability, and hospitalization requirements — and why Artiva is targeting rheumatoid arthritis and other autoimmune diseases with a single scalable platform derived from umbilical cord units.

Key Questions Answered

• •Allogeneic NK cell manufacturing: Artiva derives NK cells from umbilical cord units, scaling one unit into thousands of doses. This eliminates the patient-specific apheresis and multi-week manufacturing delay that causes disease progression in autologous CAR-T patients, while dramatically reducing cost-of-goods from the current $100,000+ price point toward community-accessible pricing.
• •NK vs. T cell safety profile: NK cells eliminate B cells without triggering cytokine release syndrome or ICANS — the two serious adverse events requiring hospitalization in CAR-T therapy. This tolerability difference allows Artiva to administer infusions in rheumatology clinic chairs, sending patients home the same day rather than admitting them to hospital or ICU settings.
• •Autoimmune immune reset mechanism: German academic research published in 2022 demonstrated that complete B cell depletion in autoimmune patients produces an immune reset — B cells reconstitute with a naive phenotype, delivering complete disease relief in conditions including lupus, RA, myositis, and scleroderma. Artiva is running a basket trial across all four indications simultaneously.
• •Indication selection framework: When choosing which disease to pursue first, Aslan recommends three filters — prioritize transformational over incremental efficacy, enter low-competition spaces where differentiation is clear, and map all the way to commercialization before starting trials to ensure each data package eliminates major downstream risks rather than deferring them.
• •2026 pipeline milestones: Artiva has two near-term catalysts: releasing RA efficacy data confirming B cell depletion translates to clinical response, and initiating FDA discussions on registrational trial design. Positive outcomes on both would trigger parallel workstreams in physician education, reimbursement strategy, and manufacturing scale-up in preparation for a potential commercial launch.